Prof. Dr. Saadettin Kılıçkap

Bilimsel Yayınlar

Bibliyografik kayıtlar özgün dilinde sunulmuştur.

Uluslararası dergilerdeki makaleler

1. The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer. Cengiz M., BOZKURT O., NURANSOY CENGİZ A., İNANÇ M., ÖZKAN M., Mutlu Ozkan E., et al. Discover Oncology , vol.17, no.1, 2026 (SCI-Expanded, Scopus)
2. Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients. Cengiz M., BOZKURT O., Cengiz A. N., GÜVEN D. C., Sahin E., Ozkan E. M., et al. Scientific Reports , vol.16, no.1, 2026 (SCI-Expanded, Scopus)
3. Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab. KÖLEMEN E., UYGUN K., ÇABUK D., ERMAN M., Kılıçkap S., KÖŞECİ T., et al. Discover Oncology , vol.17, no.1, 2026 (SCI-Expanded, Scopus)
4. Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician–patient survey. Cicin I., Bahsi T., Kose F., Kus T., ERALP Y., ÜRÜN Y., et al. Scientific Reports , vol.16, no.1, 2026 (SCI-Expanded, Scopus)
5. Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab. Ağdaş G., Bayir D., Şahin E., Cengiz M., GÜVEN D. C., Demir M. S., et al. Scientific Reports , vol.16, no.1, 2026 (SCI-Expanded, Scopus)
6. Intracholecystic Papillary Neoplasm Mimicking High-Grade Dedifferentiation in a Patient With Neuroendocrine Tumor: The Value of Dual-Tracer PET/CT. Simsir C., YILMAZ K., Kılıçkap S., Onur R. M., TUNCEL M. Clinical Nuclear Medicine , vol.51, no.11, 2026 (SCI-Expanded, Scopus)
7. Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study. Demircan N. C., Özdemir M., Ballı S., Köse Baytemur N., Helvacı K., Akbaş S., et al. Journal of Immunotherapy , vol.49, no.8, pp.307-313, 2026 (SCI-Expanded, Scopus)
8. Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group. Fidan M. C., Keskin Uzundere F., Biter S., Durnalı A., Kalacı E., ODABAŞI BÜKÜN H., et al. JCO Global Oncology , vol.12, no.9, 2026 (ESCI, Scopus)
9. Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group. Tunbekici S., Bal H., Kınıkoglu O., Arvas H., Muglu H., BİLİCİ A., et al. Clinical and Translational Oncology , vol.28, no.8, pp.3160-3169, 2026 (SCI-Expanded, Scopus)
10. Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature. Kıkılı C. İ., Araz M., ÜRÜN Y., BAŞARAN M., Şener N., Yazar A., et al. Clinical Genitourinary Cancer , vol.24, no.5, 2026 (SCI-Expanded, Scopus)
11. Performance-based activities of daily living using the Londrina ADL protocol in non-small cell lung cancer: A prospective cross-sectional controlled study: Performance-based ADL in NSCLC. ŞAHİN YILDIZ H., SAĞLAM M., VARDAR YAĞLI N., Kilic K., ÇALIK E., İNAL İNCE D., et al. Medicine , vol.105, no.31, 2026 (SCI-Expanded, Scopus)
12. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study. Köylü B., Celayir Ö. M., Muğlu H., Can O., Şen F., Öven B. B., et al. Cancers , vol.18, no.12, 2026 (SCI-Expanded, Scopus)
13. Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis. Güzel H. G., Kıvrak Salim D., Kılıçkap S., Kemal Y., Akosman C., Köseoğlu Ç., et al. Oncologist , vol.31, no.4, 2026 (SCI-Expanded, Scopus)
14. Investigating the feasibility of cascade genetic testing for BRCA1/2 in Türkiye: physicians' practices, barriers, and solutions. Cicin I., Kus T., ERALP Y., ÜRÜN Y., Demirci U., Bahsi T., et al. European Journal of Cancer Care , vol.2026, 2026 (SCI-Expanded, SSCI, Scopus)
15. Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer. NURANSOY CENGİZ A., BOZKURT O., Cengiz M., ÖZKAN M., İNANÇ M., KEFELİ U., et al. Journal of Clinical Medicine , vol.15, no.2, 2026 (SCI-Expanded, Scopus)
16. Dermoscopic and Histopathological Features of Melanocytic Lesions in Melanoma Patients Undergoing Adjuvant Systemic Therapy. Yalcin H. B., Balan K., GÖKÖZ Ö., Elcin G., DİZDAR Ö., Kılıckap S., et al. Dermatology Practical and Conceptual , vol.16, no.1, 2026 (SCI-Expanded, Scopus)
17. Impact of renin–angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non–small cell lung cancer. Mutlu Ozkan E., Karadağ I., Sahın E., NURANSOY CENGİZ A., Cengız M., Can Guven D., et al. Expert Review of Anticancer Therapy , vol.26, no.7, pp.929-936, 2026 (SCI-Expanded, Scopus)
18. Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study. Uysal M., Saglam S., Beypınar İ., Saglam E. K., Mammadov E., Ocak B., et al. Cancer Investigation , vol.44, no.2, pp.127-135, 2026 (SCI-Expanded, Scopus)
19. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial. Peters S., Gadgeel S. M., Mok T., Nadal E., KILIÇKAP S., Swalduz A., et al. NATURE MEDICINE , vol.30, pp.1923-1932, 2024 (SCI-Expanded, Scopus)
20. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG). YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., et al. Clinical Genitourinary Cancer , vol.22, no.3, 2024 (SCI-Expanded, Scopus)
21. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy. KILIÇKAP S., Ozturk A., Karadurmus N., KORKMAZ T., YUMUK P. F., ÇİÇİN İ., et al. MEDICINE , vol.103, no.21, 2024 (SCI-Expanded, Scopus)
22. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study. Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., et al. International Journal of Clinical Oncology , vol.29, no.3, pp.258-265, 2024 (SCI-Expanded, Scopus)
23. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Zhou C., Hu Y., Arkania E., Kilickap S., Ying K., Xu F., et al. Cancer cell , vol.42, no.2, pp.198-208, 2024 (SCI-Expanded, Scopus)
24. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing. KÖSTEK O., Demirel A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al. Journal of Chemotherapy , vol.36, no.7, pp.613-621, 2024 (SCI-Expanded, Scopus)
25. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study. Guven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvaci K., DURSUN B., et al. Cancer Medicine , vol.13, no.1, 2024 (SCI-Expanded, Scopus)
26. Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye. Cicin I., Karadurmus N., BİLİCİ A., Bahsi T., ŞENDUR M. A. N., Demirci U., et al. FUTURE ONCOLOGY , vol.20, no.15, pp.1031-1045, 2024 (SCI-Expanded, Scopus)
27. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab. YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al. Journal of Immunotherapy and Precision Oncology , vol.6, no.4, pp.170-176, 2023 (Scopus)
28. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study. GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.149, no.7, pp.3599-3606, 2023 (SCI-Expanded, Scopus)
29. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors. GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al. Anti-Cancer Drugs , vol.34, no.6, pp.783-790, 2023 (SCI-Expanded, Scopus)
30. Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study. ÖZDEMİR N., AKTAŞ B. E., Gulmez A., İNKAYA A. Ç., Bayraktar-Ekincioglu A., Kilickap S., et al. Supportive Care in Cancer , vol.31, no.3, 2023 (SCI-Expanded, Scopus)
31. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy. GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al. INTERNATIONAL JOURNAL OF CANCER , vol.152, pp.679-685, 2023 (SCI-Expanded, Scopus)
32. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. Yekedüz E., Karakaya S., Ertürk İ., Tural D., Uçar G., Şentürk Öztaş N., et al. Clinical Genitourinary Cancer , vol.21, no.1, pp.175-182, 2023 (SCI-Expanded, Scopus)
33. Intracerebral de novo arterio-venous malformations as a side effect of bevacizumab. Elmali A., GÖÇMEN R., KILIÇKAP S., YAZICI G. Journal of Oncology Pharmacy Practice , 2023 (SCI-Expanded, Scopus)
34. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study. YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al. BREAST , vol.66, pp.85-88, 2022 (SCI-Expanded, Scopus)
35. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study. Yekeduz E., Tural D., Erturk I., Karakaya S., EROL C., Ercelep O., et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.12, pp.3537-3546, 2022 (SCI-Expanded, Scopus)
36. Oncologists' attitudes towards prophylaxis of cancer associated venous thromboembolism: A prospective, descriptive study. Kandemir E. A., EKİNCİOĞLU A., KILIÇKAP S. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.7, pp.1560-1567, 2022 (SCI-Expanded, Scopus)
37. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors. Yucel K. B., Yekeduz E., Karakaya S., Tural D., Erturk I., EROL C., et al. SCIENTIFIC REPORTS , vol.12, no.1, 2022 (SCI-Expanded, Scopus)
38. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy. GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al. JOURNAL OF CLINICAL MEDICINE , vol.11, no.15, 2022 (SCI-Expanded, Scopus)
39. Severe progressive dermatomyositis in a patient with metastatic ovarian cancer using bevacizumab. MENTEŞOĞLU D., DOĞAN GÜNAYDIN S., ERSOY EVANS S., Atakan N., GÖKÖZ Ö., KARADAĞ Ö., et al. INDIAN JOURNAL OF PHARMACOLOGY , vol.54, no.4, pp.295-296, 2022 (SCI-Expanded, Scopus)
40. Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. Gurbuz M., Akkus E., Sakin A., Urvay S., Demiray A. G., Sahin S., et al. JOURNAL OF GASTROINTESTINAL CANCER , vol.53, no.2, pp.282-288, 2022 (ESCI, Scopus)
41. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy. GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.4, pp.785-793, 2022 (SCI-Expanded, Scopus)
42. The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis. GÜVEN D. C., ŞAHİN T. K., Erul E., KILIÇKAP S., Gambichler T., AKSOY S. CANCERS , vol.14, no.11, 2022 (SCI-Expanded, Scopus)
43. Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.. Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Erman M., Urun Y., et al. JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.6, 2022 (SCI-Expanded, Scopus)
44. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study. Yekeduz E., Ozbay M. F., Caglayan D., Yildirim A., Erol C., Yildirim H. C., et al. JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.4, 2022 (SCI-Expanded, Scopus)
45. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer. Esen S. A., Ergun Y., Erol C., Arikan R., Er M. M., Atci M. M., et al. Bosnian Journal of Basic Medical Sciences , vol.22, no.5, pp.818-825, 2022 (SCI-Expanded, Scopus)
46. Pazopanib-induced chylothorax in a patient with renal cell carcinoma. KÖYLÜ B., TEKİN F., AKTAŞ B. Y., KILIÇKAP S., KÖKSAL D. ANTI-CANCER DRUGS , vol.33, no.1, 2022 (SCI-Expanded, Scopus)
47. Thirty-day mortality rates after immunotherapy initiation. SÜTCÜOĞLU O., Ilhan A., Tacar S. Y., GÜVEN D. C., Ucar G., Karadurmus N., et al. IMMUNOTHERAPY , vol.13, pp.1419-1426, 2021 (SCI-Expanded, Scopus)
48. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., et al. FUTURE ONCOLOGY , vol.17, pp.4861-4869, 2021 (SCI-Expanded, Scopus)
49. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study. GÜVEN D. C., Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K., EROL C., et al. CURRENT PROBLEMS IN CANCER , vol.45, no.6, 2021 (SCI-Expanded, Scopus)
50. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme. GÜVEN D. C., AKSUN M. S., ÇAKIR İ. Y., KILIÇKAP S., KERTMEN N. FUTURE ONCOLOGY , vol.17, pp.4405-4413, 2021 (SCI-Expanded, Scopus)
51. Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review. GÜVEN D. C., ŞAHİN T. K., KILIÇKAP S., Uckun F. M. FRONTIERS IN ONCOLOGY , vol.11, 2021 (SCI-Expanded, Scopus)
52. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality. GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al. BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus)
53. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al. SUPPORTIVE CARE IN CANCER , vol.29, no.9, pp.5417-5423, 2021 (SCI-Expanded, Scopus)
54. Initiation of Chemosaturation With Percutaneous Hepatic Perfusion Program in Interventional Radiology Department. ÖCAL O., Eldem G., KARAGÖZ A. H., KILIÇKAP S., YALÇIN Ş., BALKANCI F., et al. CUREUS , vol.13, no.9, 2021 (ESCI)
55. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors. GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al. BIOMARKERS IN MEDICINE , vol.15, no.13, pp.1123-1130, 2021 (SCI-Expanded, Scopus)
56. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab. Tural D., Olmez O. F., Sumbul A. T., Ozhan N., ÇAKAR B., Kostek O., et al. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.26, pp.1506-1513, 2021 (SCI-Expanded, Scopus)
57. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience. Bahceci A., PAYDAŞ S., Ak N., Ferhatoglu F., Saip P. M., SEYDAOĞLU G., et al. CANCER INVESTIGATION , vol.39, no.6-7, pp.473-481, 2021 (SCI-Expanded, Scopus)
58. Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report. GÜVEN D. C., KILIÇKAP S., YILDIRIM H. Ç., Ceylan F., BAŞ O., DİZDAR Ö. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.27, no.5, pp.1281-1283, 2021 (SCI-Expanded, Scopus)
59. Comparison of respiratory muscle strength and endurance, maximal oxygen consumption, and fatigue in colorectal cancer survivors with healthy adults. Sanver M. F., VARDAR YAĞLI N., SAĞLAM M., TEKERLEK H., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., et al. SUPPORTIVE CARE IN CANCER , vol.29, no.7, pp.3903-3909, 2021 (SCI-Expanded, Scopus)
60. The effect of the COVID-19 pandemic on routine adult vaccination in cancer patients. ÖZDEMİR N., Bayraktar-Ekincioglu A., KILIÇKAP S. MEDICAL ONCOLOGY , vol.38, no.6, 2021 (SCI-Expanded, Scopus)
61. Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.. Ozguroglu M., Sezer A., Kilickap S., Gumus M., Bondarenko I., Gogishvili M., et al. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021 (SCI-Expanded, Scopus)
62. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY. GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al. NEPHROLOGY DIALYSIS TRANSPLANTATION , vol.36, 2021 (SCI-Expanded, Scopus)
63. Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.. Gumus M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., Ozguroglu M., et al. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.15, 2021 (SCI-Expanded, Scopus)
64. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., et al. SUPPORTIVE CARE IN CANCER , vol.29, no.4, pp.2029-2035, 2021 (SCI-Expanded, Scopus)
65. Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy. Kandemir E. A., EKİNCİOĞLU A., KILIÇKAP S. SUPPORTIVE CARE IN CANCER , vol.29, no.3, pp.1699-1709, 2021 (SCI-Expanded, Scopus)
66. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Sezer A., KILIÇKAP S., GÜMÜŞ M., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., et al. LANCET , vol.397, no.10274, pp.592-604, 2021 (SCI-Expanded, Scopus)
67. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.. Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., et al. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021 (SCI-Expanded, Scopus)
68. Factors affecting the response to Y-90 microsphere therapy in the cholangiocarcinoma patients. Bozkurt M., Eldem G., Bozbulut U. B., BOZKURT M. F., KILIÇKAP S., PEYNİRCİOĞLU B., et al. RADIOLOGIA MEDICA , vol.126, no.2, pp.323-333, 2021 (SCI-Expanded, Scopus)
69. Factors Affecting Survival in Retroperitoneal Sarcomas Treated with Upfront Surgery: A Real-World Study by Turkish Oncology Group. Akagunduz B., AKIN TELLİ T., YILDIRIM H. Ç., SEZGİN GÖKSU S., DEMİR N., Hafizoglu E., et al. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.31, no.2, pp.92-98, 2021 (SCI-Expanded, Scopus, TRDizin)
70. Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study). HIZAL M., ŞENDUR M. A. N., YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.7, pp.1583-1589, 2020 (SCI-Expanded, Scopus)
71. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., et al. LUNG CANCER , vol.148, pp.48-54, 2020 (SCI-Expanded, Scopus)
72. Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives. C Guven D., ŞAHİN T. K., DİZDAR Ö., KILIÇKAP S. BIOMARKERS IN MEDICINE , vol.14, pp.1383-1392, 2020 (SCI-Expanded, Scopus)
73. Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19. GÜVEN D. C., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., AKSOY S., KILIÇKAP S. FRONTIERS IN ONCOLOGY , vol.10, 2020 (SCI-Expanded, Scopus)
74. Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer. Uruen Y., Hussain S. A., Bakouny Z., Castellano D., KILIÇKAP S., Morgan G., et al. JCO GLOBAL ONCOLOGY , vol.6, pp.1248-1257, 2020 (ESCI, Scopus)
75. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey. Hacioglu M. B., Kostek O., Karabulut S., Tastekin D., SEZGİN GÖKSU S., Alandag C., et al. JOURNAL OF BUON , vol.25, no.4, pp.1897-1903, 2020 (SCI-Expanded, Scopus)
76. The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis. Eren M. F., Eren A. A., Sayan M., YÜCEL B., Elagoz S., Ozguven Y., et al. MEDICINA-LITHUANIA , vol.56, no.7, 2020 (SCI-Expanded, Scopus)
77. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer. YAŞAR H. A., Yucel K. B., Arslan C., Ucar G., Karakaya S., Bilgin B., et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.5, pp.1110-1116, 2020 (SCI-Expanded, Scopus)
78. Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic. Kucuk E., EKİNCİOĞLU A., ERMAN M., KILIÇKAP S. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.3, pp.595-602, 2020 (SCI-Expanded, Scopus)
79. Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study. Yasar H. A., Turna H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.2, pp.267-272, 2020 (SCI-Expanded, Scopus)
80. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient. KILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.2, pp.496-499, 2020 (SCI-Expanded, Scopus)
81. Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience. Karakas Y., Lacin S., KURTULAN O., Esin E., Sunar V., SÖKMENSÜER C., et al. TURKISH JOURNAL OF GASTROENTEROLOGY , vol.31, no.2, pp.91-98, 2020 (SCI-Expanded, Scopus, TRDizin)
82. The Effects of Different Treatment Modalities on the Disease Course and Survival in Patients with Hepatocellular Cancer. Lacin S., Karakas Y., DİZDAR Ö., KILIÇKAP S., Hassan M. M., Xiao L., et al. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.30, no.2, pp.94-102, 2020 (SCI-Expanded, Scopus, TRDizin)
83. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer. GÜVEN D. C., KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.1, pp.256-258, 2020 (SCI-Expanded, Scopus)
84. Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter?. ÜRÜN Y., Yasar H. A., TURNA Z. H., KILIÇKAP S., Sezer A., Oksuzoglu B., et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.25, no.8, pp.2062-2063, 2019 (SCI-Expanded, Scopus)
85. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study. ÜRÜN Y., Yasar H. A., TURNA Z. H., Esin E., Sedef A. M., Alkan A., et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.25, no.7, pp.1658-1664, 2019 (SCI-Expanded, Scopus)
86. Adaptation of Error Adjusted Bagging Method for Prediction. Isikhan S., KARABULUT E., Samadi A., KILIÇKAP S. INTERNATIONAL JOURNAL OF DATA WAREHOUSING AND MINING , vol.15, no.3, pp.28-45, 2019 (SCI-Expanded, Scopus)
87. Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability. KILIÇKAP S., Onder S., DİZDAR Ö., ERMAN M., ÜNER A. CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.83, no.6, pp.1195-1196, 2019 (SCI-Expanded, Scopus)
88. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience. TÜRK G., Eldem G., KILIÇKAP S., Bozkurt F. M., VOLKAN SALANCI B., ÇİL B. E., et al. JOURNAL OF GASTROINTESTINAL CANCER , vol.50, no.2, pp.236-243, 2019 (ESCI, Scopus)
89. Analysis of Fusobacterium nucleatum and Streptococcus gallolyticus in saliva of colorectal cancer patients. Guven D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al. BIOMARKERS IN MEDICINE , vol.13, no.9, pp.725-735, 2019 (SCI-Expanded, Scopus)
90. Reproductive cancer risk factors among relatives of cancer patients in a tertiary oncology center. Atta N., KILIÇKAP S., YÜCE D., Hayran M. BMC CANCER , vol.19, 2019 (SCI-Expanded, Scopus)
91. Critical Role of Ga-68 DOTATATE PET-CT in a Patient with Neuroendocrine Tumor and Second Primary Cancer. TELLİ T., TUNCEL M., KILIÇKAP S. TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM , vol.23, no.1, pp.58-63, 2019 (ESCI, Scopus, TRDizin)
92. Sicca/Sjogren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Ramos-Casals M., Maria A., Suarez-Almazor M. E., Lambotte O., Fisher B. A., Hernandez-Molina G., et al. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , vol.37, no.3, 2019 (SCI-Expanded, Scopus)
93. EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN TREATMENT OF NON-SMALL CELL LUNG CANCER. KILIÇKAP S. NOBEL MEDICUS , vol.14, no.3, pp.5-8, 2018 (ESCI, Scopus)
94. Factors associated with quitting action following smoking cessation counseling.. Hayran K. M., Yuce D., Erman M., Dizdar O., Kilickap S., HUSEYIN B. JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15, 2018 (SCI-Expanded, Scopus)
95. Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: Single center real life results. ARMAĞAN B., SARI A., ERDEN A., KILIÇ L., ERDAT E. C., KILIÇKAP S., et al. MEDICINE , vol.97, no.13, 2018 (SCI-Expanded, Scopus)
96. Changes in lifestyle upon diagnosis of cancer or other chronic illnesses: A Turkish Oncology Group study. Turhal N. S., Akinci F., Haciabdullahoglu Y., Dolmaci M., Sari A., GÜRHAN N., et al. JOURNAL OF HEALTH PSYCHOLOGY , vol.23, no.4, pp.561-566, 2018 (SSCI, Scopus)
97. Evaluation of G-CSF (granulocyte colony stimulating factor) use in oncology outpatient clinic by the PRS (patient risk score) assessment. ARAS E., Tecen K., Bayraktar-Ekincioglu A., Demirkan K., KILIÇKAP S. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY , vol.40, no.1, pp.247, 2018 (SCI-Expanded, Scopus)
98. Epidemiyoloji ve Etiyoloji. YÜCE D., KILIÇKAP S. Türkiye Klinikleri Tip Bilimleri Dergisi , 2018 (Scopus, TRDizin)
99. Endpoints in oncology clinical trials. KILIÇKAP S., Demirci U., Karadurmus N., Dogan M., Akinci B., ŞENDUR M. A. N. JOURNAL OF BUON , vol.23, 2018 (SCI-Expanded, Scopus)
100. Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors. Tecen-Yucel K., Bayraktar-Ekincioglu A., KILIÇKAP S., ERMAN M. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.28, no.1, pp.53-60, 2018 (SCI-Expanded, Scopus, TRDizin)
101. BİR SİGARA BIRAKMA POLİKLİNİĞİNDE UYGULANAN PSİKOEĞİTİMSEL SİGARA BIRAKMA POROGRAMININ ETKİNLİĞİ. KAMIŞLI S., YÜCE D., küçükçoban ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., et al. Anadolu Hemşirelik ve Sağlık Bilimleri Dergisi , vol.20, no.4, pp.234-242, 2017 (TRDizin)
102. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient. Karakas Y., YÜCE D., KILIÇKAP S. ONCOLOGY RESEARCH AND TREATMENT , vol.40, no.10, pp.621-622, 2017 (SCI-Expanded, Scopus)
103. Reinforcement of mental health in an interaction group of cancer patients. HAYRAN K. M., Kamisli S., Kucukcoban S., ÇELİK İ., KILIÇKAP S., YÜCE D. PSYCHO-ONCOLOGY , vol.26, pp.161, 2017 (SCI-Expanded, SSCI, Scopus)
104. Cancer patients and oncology nursing from the perspectives of oncology nurses in Turkey. Kamisli S., YÜCE D., Karakilic B., KILIÇKAP S., HAYRAN K. M. PSYCHO-ONCOLOGY , vol.26, pp.145, 2017 (SCI-Expanded, SSCI, Scopus)
105. Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?. Demirci N. S., Dogan M., Erdem G. U., Kacar S., Turhan T., KILIÇKAP S., et al. SAUDI JOURNAL OF GASTROENTEROLOGY , vol.23, no.3, pp.183-189, 2017 (SCI-Expanded, Scopus)
106. Evaluation of complementary and alternative medicine trials registered in clinicaltrials.gov database. DİZDAR Ö., BİLGİN E., AKIN S., KILIÇKAP S., HAYRAN M. JOURNAL OF BUON , vol.22, no.2, pp.530-534, 2017 (SCI-Expanded, Scopus)
107. Attitudes of cancer patients after diagnosis: How cancer affects social life? A Turkish Oncology Group study. Nayir E., Koyuncu M. B., Esin E., Turker I., TANRIVERDİ Ö., UYSAL M., et al. JOURNAL OF BUON , vol.22, no.1, pp.208-213, 2017 (SCI-Expanded, Scopus)
108. A critical analysis of publication rates of national oncology meeting abstracts in Turkey. KILIÇKAP S., Hüseyin B., Esin E., YÜCE D., HAYRAN K. M. Journal of Oncological Sciences , pp.1-5, 2017 (TRDizin)
109. A giant polypoid mass leading to obstruction in the colon. KÖKLÜ H., ÖZTÜRK Ö., Koklu S., Saglam A., KARÇAALTINCABA M., KILIÇKAP S. ACTA GASTRO-ENTEROLOGICA BELGICA , vol.80, no.1, pp.93-94, 2017 (SCI-Expanded, Scopus)
110. Retention Rate of Etanercept in Patients with Rheumatoid Arthritis Is Better Than That of Monoclonal Antibody. ERDEN A., KILIÇ L., KARADAĞ Ö., KİRAZ S., KILIÇKAP S., AKDOĞAN A., et al. Acta Medica , vol.48, no.3, pp.11-17, 2017 (TRDizin)
111. Evaluation of risk factors for the recurrence of colorectal polyps and colorectal cancer. ATEŞ Ö., SİVRİ B., KILIÇKAP S. TURKISH JOURNAL OF MEDICAL SCIENCES , vol.47, no.5, pp.1370-1376, 2017 (SCI-Expanded, Scopus, TRDizin)
112. Does Adjuvant Hormone Therapy Improve Survival in Epithelial Ovarian Cancer?. KILIÇKAP S., Tural D. JOURNAL OF CLINICAL ONCOLOGY , vol.34, no.17, pp.2069-2070, 2016 (SCI-Expanded, Scopus)
113. Tendency of cancer patients and their relatives to use Internet for health-related searches: Turkish Oncology Group (TOG) Study. Nayir E., TANRIVERDİ Ö., Karakas Y., KILIÇKAP S., Turhal N. S., Avci N., et al. JOURNAL OF BUON , vol.21, no.3, pp.714-719, 2016 (SCI-Expanded, Scopus)
114. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. ATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., et al. JOURNAL OF BUON , vol.21, no.2, pp.375-381, 2016 (SCI-Expanded, Scopus)
115. Akciğer Kanserinde Erken Tanı ve Tarama Programlarındaki Gelişmeler. YÜCE D., KILIÇKAP S. Turkiye Klinikleri Journal of Medical Oncology Special Topics , vol.9, no.4, pp.1-5, 2016 (TRDizin)
116. Anthracyclin - Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75. Sarici F., KERTMEN N., Aslan A. C., Tasdemir V., BABACAN T., KILIÇKAP S., et al. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.2, pp.89-95, 2016 (SCI-Expanded, Scopus, TRDizin)
117. The Prognostic Value of High Pretreatment Plasma D-Dimer Levels in Non-Metastatic Breast Cancer Patients with Absence of Venous Thromboembolism. Kacan T., YÜCEL B., BAHAR S., Celasun G., Seker M. M., Babacan N., et al. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.3, pp.136-144, 2016 (SCI-Expanded, Scopus, TRDizin)
118. The Relationship of Agmatine Deficiency with the Lung Cancer. KAPANCIK S., ÇELİK V. K., KILIÇKAP S., Kacan T., Kapancik S. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.2, pp.103-109, 2016 (SCI-Expanded, Scopus, TRDizin)
119. Effect of Zoledronic Acid on Rats' Tissue SDF-1 Expression. Arik Z., KILIÇKAP S., AKPULAT U., Nahit Sendur M. A., KOCAEFE Y. Ç., ERMAN M. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.4, pp.215-219, 2016 (SCI-Expanded, Scopus, TRDizin)
120. The prognostic value of UHRF-1 and p53 in gastric cancer. AKGÜL BABACAN N., EĞİLMEZ H. R., YÜCEL B., Parlak I., ŞEKER M. M., KAÇAN T., et al. SAUDI JOURNAL OF GASTROENTEROLOGY , vol.22, no.1, pp.25-29, 2016 (SCI-Expanded, Scopus)
121. Significant Association Between Polymorphisms of Wnt Antagonist Genes and Lung Cancer. YILMAZ M., DÖNMEZ G., KAÇAN T., SARI İ., Babacan N. A., SARİ M., et al. JOURNAL OF INVESTIGATIVE MEDICINE , vol.63, no.8, pp.935-941, 2015 (SCI-Expanded, Scopus)
122. Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study. Abali H., ÇELİK İ., Karaca B., TURNA Z. H., Saglam E. K., Akman T., et al. JOURNAL OF BUON , vol.20, no.4, pp.1137-1141, 2015 (SCI-Expanded, Scopus)
123. QUALITY OF LIFE DOMAINS ASSOCIATED WITH READMISSION. HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., et al. VALUE IN HEALTH , vol.18, no.3, 2015 (SCI-Expanded, SSCI, Scopus)
124. Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter. Zoto T., KILIÇKAP S., YAŞAR Ü., ÇELİK İ., BOZKURT A., BABAOĞLU M. Ö. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY , vol.116, no.4, pp.354-360, 2015 (SCI-Expanded, Scopus)
125. A Case of Multifocal Skin Metastases from Lung Cancer Presenting with Vasculitic-type Cutaneous Nodule. AKGÜL BABACAN N., KILIÇKAP S., Sene S., KAÇAN T., YÜCEL B., EREN M. F., et al. INDIAN JOURNAL OF DERMATOLOGY , vol.60, no.2, 2015 (SCI-Expanded, Scopus)
126. Mortality in Colorectal Cancer and Use of Statins. Tural D., KILIÇKAP S. JOURNAL OF CLINICAL ONCOLOGY , vol.33, no.7, pp.810, 2015 (SCI-Expanded, Scopus)
127. First-Line Crizotinib in ALK-Positive Lung Cancer. Tural D., KILIÇKAP S. NEW ENGLAND JOURNAL OF MEDICINE , vol.372, no.8, pp.781, 2015 (SCI-Expanded, Scopus)
128. Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CML. Malkan U. Y., AKSU S., Aktimur S. H., Atay H., Bektas O., BÜYÜKAŞIK Y., et al. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.25, no.4, pp.215-221, 2015 (SCI-Expanded, Scopus, TRDizin)
129. Nationwide Smoking Cessation Treatment Support Program - Turkey project. ÇELİK İ., YÜCE D., Hayran M., ERMAN M., KILIÇKAP S., BUZĞAN T., et al. HEALTH POLICY , vol.119, no.1, pp.50-56, 2015 (SCI-Expanded, SSCI, Scopus)
130. ASSOCIATION OF HEALTH CARE COST WITH QUALITY OF LIFE FOR VARIOUS TYPES OF CANCERS. HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., et al. VALUE IN HEALTH , vol.17, no.7, 2014 (SCI-Expanded, SSCI, Scopus)
131. HEALTH RELATED QUALITY OF LIFE IN CANCER PATIENTS: EVALUATION WITH A SELF-ADMINISTERED IPAD APPLICATION. YÜCE D., HAYRAN K. M., KILIÇKAP S., ERMAN M., ÇELİK İ. VALUE IN HEALTH , vol.17, no.7, 2014 (SCI-Expanded, SSCI, Scopus)
132. Study of interaction with a group of cancer patients: guiding cancer patients through psychoeducational interventions. Kamisli S., HAYRAN K. M., Kucukcoban S., KILIÇKAP S., YÜCE D., ÇELİK İ. EUROPEAN JOURNAL OF ONCOLOGY NURSING , vol.18, 2014 (SCI-Expanded, SSCI, Scopus)
133. Bone Metastasis from Gastric Cancer: The Incidence, Clinicopathological Features, and Influence on Survival. Turkoz F. P., Solak M., KILIÇKAP S., Ulas A., Esbah O., Oksuzoglu B., et al. JOURNAL OF GASTRIC CANCER , vol.14, no.3, pp.164-172, 2014 (ESCI, Scopus)
134. P95 HER2 fragments and breast cancer outcome. Tural D., Akar E., Mutlu H., KILIÇKAP S. EXPERT REVIEW OF ANTICANCER THERAPY , vol.14, no.9, pp.1089-1096, 2014 (SCI-Expanded, Scopus)
135. Mortality in Prostate Cancer and Use of Statins. Tural D., YÜCE D., KILIÇKAP S. JOURNAL OF CLINICAL ONCOLOGY , vol.32, no.21, pp.2274, 2014 (SCI-Expanded, Scopus)
136. End-of-study results of Turkish gastric cancer patients from the global REGATE study. YALÇIN Ş., Gumus M., KILIÇKAP S., Alkis N., Ilhan M., Oksuzoglu B., et al. JOURNAL OF BUON , vol.19, no.2, pp.377-387, 2014 (SCI-Expanded, Scopus)
137. Lack of Association between the MTHFR C677T Polymorphism and Lung Cancer in a Turkish Population. YILMAZ M., KAÇAN T., SARI İ., KILIÇKAP S. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.15, pp.6333-6337, 2014 (SCI-Expanded, Scopus)
138. Higher Ki67 Expression is Associates With Unfavorable Prognostic Factors and Shorter Survival in Breast Cancer. KILIÇKAP S., KAYA Y., YÜCEL B., TUNCER E., AKGÜL BABACAN N., Elagoz S. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.3, pp.1381-1385, 2014 (SCI-Expanded, Scopus)
139. Lung Cancer in Women: A Single Institution Experience with 50 Patients. AKGÜL BABACAN N., YÜCEL B., KILIÇKAP S., ŞEKER M. M., KAÇAN T., KOÇ OLÇAŞ İ., et al. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.15, no.1, pp.151-154, 2014 (SCI-Expanded, Scopus)
140. Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients. KESİKLİ S. A., KILIÇKAP S. PROTEIN AND PEPTIDE LETTERS , vol.20, no.12, pp.1345-1359, 2013 (SCI-Expanded, Scopus)
141. Dose-dense effect: other contributors. KESİKLİ S. A., YÜCE D., KILIÇKAP S. LANCET ONCOLOGY , vol.14, no.12, 2013 (SCI-Expanded, Scopus)
142. Aromatase Inhibitors and Safety: Clinical or Statistical Significance?. Esin E., YÜCE D., KILIÇKAP S., ERMAN M. JOURNAL OF CLINICAL ONCOLOGY , vol.31, no.27, pp.3439, 2013 (SCI-Expanded, Scopus)
143. Evaluation of Quality of Life in Turkish Patients with Head and Neck Cancer. Akkas E. A., YÜCEL B., KILIÇKAP S., ALTUNTAŞ E. E. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.14, no.8, pp.4805-4809, 2013 (SCI-Expanded, Scopus)
144. Lack of Relationships between FGF19 Staining Pattern, Lymph Node Metastasis and Locally Invasive Characteristics of the Tumor in Colorectal Cancers. UNAL H. U., Demiralay E., Tepeoglu M., Fidan C., KILIÇKAP S. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , vol.14, no.5, pp.3151-3154, 2013 (SCI-Expanded, Scopus)
145. Long-term complications in Hodgkin's lymphoma survivors. KILIÇKAP S., BARIŞTA İ., Ulger S., ÇELİK İ., SELEK U., Gullu I., et al. TUMORI , vol.98, no.5, pp.601-606, 2012 (SCI-Expanded, Scopus)
146. Gastric cancer after cadaveric liver transplantation in a patient with autoimmune hepatitis: A case report and review of the literature. ARSLAN Ç., KILIÇKAP S., YALÇIN Ş. TURKISH JOURNAL OF GASTROENTEROLOGY , vol.22, no.1, pp.73-76, 2011 (SCI-Expanded, Scopus, TRDizin)
147. Isolated Bone Metastases in Early Stage Endometrial Adenocarcinoma: A Case Report and Review of the Literature. Kurt M., KILIÇKAP S., AKSOY S., ERMAN M., Gedikoglu G., Turker A. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.21, no.1, pp.52-56, 2011 (SCI-Expanded, Scopus, TRDizin)
148. The First Line Systemic Chemotherapy in Metastatic Gastric Carcinoma: A Comparison of Docetaxel, Cisplatin and Fluorouracil (DCF) Versus Cisplatin and Fluorouracil (CF); Versus Epirubicin, Cisplatin and Fluorouracil (ECF) Regimens in Clinical Setting. KILIÇKAP S., YALÇIN Ş., ATEŞ Ö., Tekuzman G. HEPATO-GASTROENTEROLOGY , vol.58, no.105, pp.208-212, 2011 (SCI-Expanded, Scopus)
149. Socio-demographic parameters in screening for breast cancer: Lessons from a population-based women's Health Project held in a province in Turkey. HAYRAN K. M., Abali H., KILIÇKAP S., MENTEŞ T., Aksoy H., Kemik A., et al. JOURNAL OF BUON , vol.15, no.4, pp.726-731, 2010 (SCI-Expanded, Scopus)
150. The Effect on Prognosis of Postoperative CA 19-9 Level in Patients With Pancreatic Cancer. KILIÇKAP S., ARSLAN Ç. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , vol.33, no.3, pp.320, 2010 (SCI-Expanded, Scopus)
151. Fitting the Pieces of the POEMS Syndrome Jigsaw Puzzle-Guillain-Barre Syndrome in a Patient with Refractory Ascites: Case Report. Shorbagi A., ÖNAL İ. K., Onal E. D., KILIÇKAP S., BARIŞTA İ., Kansu T., et al. TURKIYE KLINIKLERI TIP BILIMLERI DERGISI , vol.30, no.1, pp.352-355, 2010 (SCI-Expanded, Scopus)
152. A case of recurrent metastatic hepatocellular cancer controlled with immunotherapy and antiviral therapy following resection. KILIÇKAP S., Kars A., HAMALOĞLU E., ŞİMŞEK H. MEDICAL ONCOLOGY , vol.26, no.4, pp.501-505, 2009 (SCI-Expanded, Scopus)
153. Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients. KILIÇKAP S., ARSLAN Ç. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION , vol.301, no.14, pp.1435, 2009 (SCI-Expanded, Scopus)
154. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma. KILIÇKAP S., Yavuz B., AKSOY S., Sahiner L., DİNÇER M., HARPUTLUOĞLU H., et al. MEDICAL ONCOLOGY , vol.25, no.4, pp.437-442, 2008 (SCI-Expanded, Scopus)
155. Platelet size has diagnostic predictive value for bone marrow metastasis in patients with solid tumors. AKSOY S., KILIÇKAP S., Hayran M., HARPUTLUOĞLU H., KOCA E., Dede D. S., et al. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY , vol.30, no.3, pp.214-219, 2008 (SCI-Expanded, Scopus)
156. A case report: zoledronic acid-induced anterior uveitis. KILIÇKAP S., Ozdamar Y., ALTUNDAĞ M. K., DİZDAR Ö. MEDICAL ONCOLOGY , vol.25, no.2, pp.238-240, 2008 (SCI-Expanded, Scopus)
157. Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C. DİZDAR Ö., Tapan U., AKSOY S., Harputluoglu H., KILIÇKAP S., BARIŞTA İ. EUROPEAN JOURNAL OF HAEMATOLOGY , vol.80, no.5, pp.381-385, 2008 (SCI-Expanded, Scopus)
158. Characteristics of breast cancer patients with central nervous system metastases: A single-center experience. Harputluoglu H., DİZDAR Ö., AKSOY S., KILIÇKAP S., Dede D. S., Ozisik Y., et al. JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION , vol.100, no.5, pp.521-526, 2008 (SCI-Expanded, Scopus)
159. Erectile dysfunction in successfully treated lymphoma patients. AKSOY S., HARPUTLUOĞLU H., KILIÇKAP S., DİNÇER M., DİZDAR Ö., AKDOĞAN B., et al. SUPPORTIVE CARE IN CANCER , vol.16, no.3, pp.291-297, 2008 (SCI-Expanded, Scopus)
160. A decision-analytic model for early stage breast cancer: Lumpectomy vs mastectomy. Alogan G. B., Elele T., Hayran M., ERMAN M., KILIÇKAP S. NEOPLASMA , vol.55, no.3, pp.222-228, 2008 (SCI-Expanded, Scopus)
161. The sign of Leser-Trelat. Kilickap S., Yalcin B. NEW ENGLAND JOURNAL OF MEDICINE , vol.356, no.21, pp.2184, 2007 (SCI-Expanded, Scopus)
162. Early and late arrhythmogenic effects of doxorubicin. Kilickap S., Barista I., Akgul E., Aytemir K., Aksoy S., Tekuzman G. SOUTHERN MEDICAL JOURNAL , vol.100, no.3, pp.262-265, 2007 (SCI-Expanded, Scopus)
163. A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient. Yilmaz R., Akoglu H., Yirkpantur A., Kilickap S., Arici M., Altun B., et al. RENAL FAILURE , vol.29, no.1, pp.103-105, 2007 (SCI-Expanded, Scopus)
164. Rituximab-related viral infections in lymphoma patients. Aksoy S., Harputluoglu H., Kilickap S., Dede D. S., Dizdar O., Altundag K., et al. LEUKEMIA & LYMPHOMA , vol.48, no.7, pp.1307-1312, 2007 (SCI-Expanded, Scopus)
165. Extensive exfoliative dermatitis induced by chlorambucil. Kilickap S., Kurt M., Aksoy S., Erman M., Turker A. AMERICAN JOURNAL OF HEMATOLOGY , vol.81, no.11, pp.891-892, 2006 (SCI-Expanded, Scopus)
166. Cutaneous metastases of signet cell carcinoma of the rectum without accompanying visceral involvement. Kilickap S., Aksoy S., Dincer M., Saglam E. A., Yalcin S. SOUTHERN MEDICAL JOURNAL , vol.99, no.10, pp.1137-1139, 2006 (SCI-Expanded, Scopus)
167. Gefitinib efficacy in relapsed small-cell lung cancer. DİNÇER M., Aksoy S., Kilickap S., Altundag K. LUNG CANCER , vol.53, no.2, pp.255, 2006 (SCI-Expanded, Scopus)
168. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Aksoy S., Abali H., Kilickap S., Erman M., Kars A. CLINICAL AND LABORATORY HAEMATOLOGY , vol.28, no.3, pp.211-214, 2006 (SCI-Expanded, Scopus)
169. Nasopharynx carcinoma complicated with pneumocephalus. Dizdar O., Kilickap S., Aksoy S., Cizginer S., Erman M. JOURNAL OF NEURO-ONCOLOGY , vol.77, no.1, pp.107-108, 2006 (SCI-Expanded, Scopus)
170. Lithium-associated hypothyroidism and thyroid papillary carcinoma: A case report. Aksoy S., Kilickap S., Erman M. SOUTHERN MEDICAL JOURNAL , vol.99, no.3, pp.279-281, 2006 (SCI-Expanded, Scopus)
171. Metastatic granular cell tumor: A case report and review of the literature. Aksoy S., Abali H., Kilickap S., HARPUTLUOĞLU H., Erman M. ACTA ONCOLOGICA , vol.45, no.1, pp.91-94, 2006 (SCI-Expanded, Scopus)
172. Acrocyanosis as a presenting symptom of Hodgkin lymphoma. Solak Y., Aksoy S., Kilickap S., Celik I. AMERICAN JOURNAL OF HEMATOLOGY , vol.81, no.2, pp.151-152, 2006 (SCI-Expanded, Scopus)
173. Nonconvulsive status epilepticus due to ifosfamide. Kilickap S., ÇAKAR M., Onal I., Tufan A., Akoglu H., Aksoy S., et al. ANNALS OF PHARMACOTHERAPY , vol.40, no.2, pp.332-335, 2006 (SCI-Expanded, Scopus)
174. Treatment of comorbidities besides the treatment of primary tumor may further increase effective management of cancer. Aksoy S., Aksoy H., HARPUTLUOĞLU H., Kilickap S., Altundag K. MEDICAL HYPOTHESES , vol.67, no.4, pp.744-746, 2006 (SCI-Expanded, Scopus)
175. Multivariate analysis of factors predictive of brain metastases in localised non-small call lung carcinoma. Kilickap S., Aksoy S., Erman M. LUNG CANCER , vol.49, no.1, pp.129, 2005 (SCI-Expanded, Scopus)
176. Successful salvage therapy of resistant gestational trophoblastic disease with ifosfamide and paclitaxel. SHORBAGİ A., Aksoy S., Kilickap S., GÜLER N. GYNECOLOGIC ONCOLOGY , vol.97, no.2, pp.722-723, 2005 (SCI-Expanded, Scopus)
177. Doxorubicin-induced second degree and complete atrioventricular block. Kilickap S., AKGUL E., Aksoy S., Aytemir K., Barista I. EUROPACE , vol.7, no.3, pp.227-230, 2005 (SCI-Expanded, Scopus)
178. Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma. Aksoy S., Abali H., Kilickap S., GÜLER N. JOURNAL OF NEURO-ONCOLOGY , vol.71, no.3, pp.333-334, 2005 (SCI-Expanded, Scopus)
179. Fludarabine phosphate may be useful in the treatment of graft-versus-host disease. Aksoy S., Abali H., Kilickap S., DİNÇER M., Erman M. MEDICAL HYPOTHESES , vol.64, no.6, pp.1150-1152, 2005 (SCI-Expanded, Scopus)
180. CA 19-9 measurement as a screening: Higher cost, lower survival. Kilickap S., Abali H., Aksoy S., Celik I. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY , vol.19, no.12, pp.1428, 2004 (SCI-Expanded, Scopus)

Uluslararası kongre bildirileri

1. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy. GÜVEN D. C., Incesu F. G. G., Yildirim H. C., Erul E., Chalabiyev E., AKTAŞ B. Y., et al. Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 9 - 13 September 2022, vol.33, (Summary Text)
2. Akciğer Kanserli Hastalarda Günlük Yaşam Aktiviteleri İle Ilişkili Parametrelerin Incelenmesi. ŞAHİN H., SAĞLAM M., VARDAR YAĞLI N., KILIÇ K., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., et al. Türk Toraks Derneği 23.Yıllık Kongresi Bildiri Kitabı, Turkey, 15 - 18 October 2020, pp.147, (Summary Text)
3. Multi-dimensional evaluation of daily living activities in lung cancer. ŞAHİN H., SAĞLAM M., VARDAR YAĞLI N., KILIÇ K., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., et al. European Respiratory Society Virtual Congress, 7 - 09 September 2020, vol.56, pp.2931, (Summary Text)
4. Evaluation of functional exercise capacity using two-field test in lung cancer patients. VARDAR YAĞLI N., KILIÇ K., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., KILIÇKAP S. European Respiratory Society Virtual Congress, 7 - 09 September 2020, vol.56, pp.278, (Summary Text)
5. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience. Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al. Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Costa Rica, 13 - 15 February 2020, vol.38, (Summary Text)
6. outcomes of patients with resected pancreatic ductal adenocarcinoma. ceylan f., GÜVEN D. C., çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A., et al. 9th international gastrointestinal cancer conference, 6 - 08 December 2019, (Full Text)
7. Gemcitabine Based Trimodality Treatment in Patients WithMuscle Invasive Bladder Cancer: Hacettepe University Experience. Esen Ç. S. B., HÜRMÜZ P., KILIÇKAP S., ÖZYİĞİT G., AKYOL H. F. 6th CONGRESS OF THEMEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM3rd INTERNATIONAL CONGRESS ON ONCOLOGICAL SCIENCES, 27 November - 01 December 2019, vol.5, (Full Text)
8. Determinants of Respiratory Muscle Strength in Lung Cancer. Kilic K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al. European-Respiratory-Society (ERS) International Congress, Madrid, Spain, 28 September - 02 October 2019, vol.54, (Summary Text)
9. Kolon kanseri tedavisi sonrası oksijen tüketimi, solunum kas kuvveti ve enduransı, fiziksel fonksiyon ve yorgunluğun incelenmesi: olgu sunumu. SANVER M. F., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., KILIÇKAP S. 7. Ulusal Fizyoterapi ve Rehabilitasyon Kongresi, Turkey, 18 - 20 April 2019, vol.30, pp.155, (Summary Text)
10. Tip 2 diyabetli bireylerin fiziksel aktivite düzeyleri ve sağlıklı yaşam biçimi davranışlarının incelenmesi. SANVER M. F., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., KILIÇKAP S. 7. Ulusal Fizyoterapi ve Rehabilitasyon Kongresi, Turkey, 18 - 20 April 2019, vol.30, pp.154-155, (Summary Text)
11. IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES. BIG DATA ANALYSIS OF 13,051 CASES (IMMUNOCANCER INTERNATIONAL REGISTRY). Ramos-Casals M., Lambotte O., Kostine M., Calabrese L., Suarez-Almazor M., Bingham C., et al. Annual European Congress of Rheumatology (EULAR), Madrid, Spain, 12 - 15 June 2019, vol.78, pp.607-608, (Summary Text)
12. Clinical features and prognosis of patients with liposarcoma: Single-center experience.. Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37, (Summary Text)
13. Akciğer kanserinde yürüme sırasındaki işin solunum kas kuvveti ile ilişkisi. VARDAR YAĞLI N., KILIÇ K., SAĞLAM M., İNAL İNCE D., ÇALIK KÜTÜKCÜ E., KILIÇKAP S. Türk Toraks Derneği 22.Yıllık Kongresi, Turkey, 10 - 14 April 2019, pp.490, (Summary Text)
14. TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY ANDRELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER. HAYRAN K. M., YÜCE D., KILIÇKAP S., houssein b., ERMAN M., DİZDAR Ö., et al. ISPOR Asia Pacific 2018, Tokyo, Japan, 8 - 11 November 2018, vol.1, pp.11, (Full Text)
15. EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE. HAYRAN K. M., YÜCE D., KILIÇKAP S., DİZDAR Ö., houssein b., ERMAN M., et al. ISPOR Asia Pacific 2018, Tokyo, Japan, 8 - 11 November 2018, (Summary Text)
16. Metastatic Choroidal Melanoma: Single Center Experience. AKTAŞ B. Y., GÜNER G., DEMİR M., GÜVEN D. C., AKTEPE O. H., BÖLEK E. Ç., et al. 2. Ulusal İmmunoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018, pp.1-48, (Full Text)
17. Respiratory muscle strength, respiratory muscle endurance, functional capacity and cognitive status in lung cancer patients. KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al. 28th European Respiratory Society Annual Congress, 15 - 19 September 2018, vol.52, pp.2477, (Summary Text)
18. Do cancer treatments affect pain perception?. KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al. 28th European Respiratory Society Annual Congress, 15 - 19 September 2018, vol.52, pp.2468, (Summary Text)
19. Analysis of Fusobacterium nucleatum, Streptococcus gallolyticus and Porphyromonas gingivalis in saliva in colorektal patients and healty controls. Abst ID:”e15117”. GÜVEN D. C., DİZDAR Ö., ALP A., Akdoğan Kittana F. N., KARAKOÇ D., Hamaloğlu E., et al. 2018 ASCO, Chicago, United States Of America, 1 - 05 June 2018, (Summary Text)
20. Yüksek Dereceli Rekürren Glial Tümör Tanılı Hastada Bevacizumabın Olası Bir Yan Etkisi Olarak Multipl Arteriovenöz Malformasyon. ELMALI DOĞAN A., MUT AŞKUN M., YÜCE SARI S., KILIÇKAP S., ZORLU A. F., YAZICI G. 13.ULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Turkey, 27 April - 01 May 2018
21. Akciğer kanserli hastalarda kognitif durumun fonksiyonel kapasite ve fiziksel aktivite ile ilişkisi. KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., ARIKAN H., İNAL İNCE D., et al. Türk Toraks Derneği 21.Yıllık Kongresi, Turkey, 11 - 15 April 2018, pp.326, (Summary Text)
22. Akciğer kanserli bireylerde solunum kas enduransının değerlendirilmesi. KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al. Türk Toraks Derneği 21.Yıllık Kongresi, Turkey, 11 - 15 April 2018, pp.324, (Summary Text)
23. Akciğer kanserli bireylerde ağrı durumunun değerlendirmesi. KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al. 1. Kardiyopulmoner Rehabilitasyon Kongresi, Turkey, 22 May - 25 November 2017, vol.29, (Summary Text)
24. Akciğer kanserinde kognitif durumun incelenmesi. KILIÇ K., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., ARIKAN H., et al. 1. Kardiyopulmoner Rehabilitasyon Kongresi, Turkey, 22 - 25 November 2017, vol.29, (Summary Text)
25. Kolorektal Kanserli Hastalarda Ve Sağlıklı Kontrollerde Tükürükte Fusobacterium Nucleatum, Streptococcus Gallolyticus Ve Porphyromonas Gingivalis Analizi. GÜVEN D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al. 7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, (Summary Text)
26. Brain Tissue Follow-up Using Dynamic Susceptibility Contrast-Enhanced and Dynamic Contrast-Enhanced Perfusion Magnetic Resonance Imaging on Lesions Categorized by Apparent Diffusion Coefficient Values in Glioblastoma. OMAY B., ARDALI S., MUT AŞKUN M., KILIÇKAP S., ERMAN M., KARLI OĞUZ H. K. Radiology Society of North America, 26 November - 01 December 2017, (Summary Text)
27. Opere evre 1A küçük hücreli dışı akciğer kanserli hastada erken nüks mü biyolojik yapıştırıcı reaksiyonu mu?. KÖKSAL D., BABAOĞLU E., KILIÇKAP S., SARINÇ ULAŞLI S., DOĞAN R. TÜSAD 2017, Turkey, 14 - 17 October 2017, (Summary Text)
28. Erlotinib tedavisine direnç gösteren akciğer kanseri olgusu. BABAOĞLU E., KILIÇKAP S., SARINÇ ULAŞLI S., KÖKSAL D. TÜSAD 2017, Turkey, 14 - 17 October 2017, (Summary Text)
29. Erlotinib tedavisine direnç gelişen akciğer adenokanseri olgusu. BABAOĞLU E., KILIÇKAP S., SARINÇ ULAŞLI S., KÖKSAL D. TÜSAD 2017, Turkey, 14 - 17 October 2017, (Summary Text)
30. Efficiency of a psychoeducational Intervention for smoking cessation in a specialized cessation clinic. YÜCE D., KAMIŞLI S., KÜÇÜKÇOBAN ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., et al. 2017 World Congress of Psycho-Oncology, 14 - 18 August 2017, (Summary Text)
31. Cancer patients and oncology nursing from the perspectives of oncology nurses in Turkey. Kamışlı S., YÜCE D., karakılıç B., KILIÇKAP S., HAYRAN K. M. 2017 World Congress of Psycho-Oncology, 14 - 18 August 2017, (Summary Text)
32. Reinforcement of mental health in an interaction group of cancer patients. HAYRAN K. M., Kamışlı S., küçükçoban ş., ÇELİK İ., KILIÇKAP S., YÜCE D. 2017 World Congress of Psycho-Oncology, 14 - 18 August 2017, (Summary Text)
33. Characteristics of Turkish colorectal cancer patients and bevacizumab preference.. Cicin I., Gumus M., Uncu D., Ozkan M., Kilickap S., Elkiran T. E., et al. 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35, (Summary Text)
34. Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation program. AKTAŞ B. Y., HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., et al. 7th ECTOH Conference on Tobacco or Health, Porto, Portugal, 22 - 25 March 2017, (Summary Text)
35. Tirozin Kinaz İnhibitörü Kaynaklı Tiroid Fonksiyon Bozukluğu. TECEN K., ÖZDEMİR N., KARA E., EKİNCİOĞLU A., DEMİRKAN S. K., ERMAN M., et al. 18. ULUSAL İÇ HASTALIKLARI KONGRESİ, Turkey, 12 - 16 October 2016, (Summary Text)
36. Using geographical information systems to describe quality of life as a function of distance in cancer patients. HAYRAN K. M., ERMAN M., KILIÇKAP S., DİZDAR Ö., YÜCE D., HÜSEYİN B., et al. ISPOR Asia Pacific Meeting 2016, 3 - 06 September 2016, vol.19, pp.892, (Summary Text)
37. Plasma caveolin-1 level: A prognostic marker for pancreatic cancer.. Demirci N. S., Dogan M., Erdem G. U., Kacar S., Turhan T., Yilmaz F. M., et al. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34, (Summary Text)
38. The clinical role of Ga-68 DOTATE PET-CT in patients with neuroendocrine tumors. TUNCEL M., KILIÇKAP S., Akdemir E. 28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Germany, 10 - 14 October 2015, vol.42, (Summary Text)
39. Adaptation of an ensemble of complementary neural networks with adjusted average error to other prediction models. YILMAZ IŞIKHAN S., KARABULUT E., KILIÇKAP S. International Society for Clinical Biostatistics 36th Annual Conference, Utrecht, Netherlands, 23 - 27 August 2015, (Summary Text)
40. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., et al. ASCO Annual Meeting, 29 May - 02 June 2015, (Full Text)
41. Turkish National Colon Cancer Registry.. Benekli M., Dumanli E., Kilickap S., Uncu D., Aliustaoglu M., Cicin I., et al. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text)
42. Association of age with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.. Benekli M., Altundag K., Dumanli E., Isikdogan A., Karaoglu A., Tekin S. B., et al. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text)
43. Factors that affect the suitability of cancer patients for clinical drug trials in Turkey: Final analysis of a multicenter study.. Erman M., Kilickap S., Ekinci A. S., Koca S., Ata A., Besen A., et al. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text)
44. Turkish National Gastric Cancer Registry.. Buyukberber S., Dumanli E., Uncu D., Ozkan M., Uslu R., Dogu G. G., et al. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text)
45. Association of obesity with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.. Coskun U., Altundag K., Aliustaoglu M., Uncu D., Ozkan M., Cicin I., et al. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text)
46. Turkish National Breast Cancer Registry.. Altundag K., Dumanli E., Aliustaoglu M., Uncu D., Ozkan M., Cicin I., et al. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text)
47. Geographic variations of clinical characteristics in breast cancer: Analysis of Turkish National Breast Cancer Registry.. Kilickap S., Altundag K., Dumanli E., Gumus M., Uslu R., Ozyilkan O., et al. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text)
48. Clinical impact of Ga-68-DOTATATE in patients with neuroendrocrine tumors. TUNCEL M., KILIÇKAP S., Akdemir E. 3rd Theranostics World Congress on Gallium-68 and PRRT, Maryland, United States Of America, 12 - 14 March 2015, vol.56, (Summary Text)
49. GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC IN THE MANAGEMENT OF CML. AKSU S., AKTİMUR S., ARİCA D., ATAY M. H., BEKTAŞ Ö., BÜYÜKAŞIK Y., et al. 20th Congress of the European Hematology Association Vienna, Austria June 11-14,2015, 11 - 14 June 2014, (Full Text)
50. The diagnostic and prognostic value of UHRF-1 and p53 in gastric cancer.. Babacan N. A., Egilmez R., Yucel B., Seker M. M., Parlak I., Kacan T., et al. 50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text)
51. Could the neutrophil to lymphocyte ratio be a poor prognostic factor for lung cancers?. Kacan T., Babacan N., Seker M. M., Yucel B., Behceci A., Gedikil M. A., et al. 50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text)
52. İYİ DİFERANSİYE TİROİT KANSERLERİNDE TSH R METİLASYONUNUN ÖNEMİ. KARTAL K., KÖSEMEHMETOĞLU K., ÖNDER S. Ç., KILIÇKAP S., GÜLER TEZEL Y. G., KAYNAROĞLU Z. V. 19. Ulusal Cerrahi Kongresi, Turkey, 16 - 20 April 2014, (Summary Text)
53. Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience. Erman M., Arik Z., Kilickap S., Bilen C. Y., Yazici S., Akdogan B., et al. Genitourinary Cancers Symposium, San-Francisco, Costa Rica, 30 January - 01 February 2014, vol.32, (Summary Text)
54. Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study. Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., et al. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30, (Summary Text)
55. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma. Kilickap S., Yavuz B., Aksoy S., Sahiner L., Harputluoglu H., Dincer M., et al. 30th Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.202, (Summary Text)

Kitaplar ve kitap bölümleri

1. esophaeal and gastroesophaeal junction tumors. YALÇIN Ş., DİZDAR Ö., KILIÇKAP S., cilbir e., philip p. a. in: textbook of gastrointestinal oncology, Suayib Yalcin, Philip a. Philip, Editor, springer, pp.55-72, 2019
2. Meslek Hastalıkları: İş ile İlgili Hastalıklar (Seçilmiş Başlıklarda). Hacettepe Üniversitesi Yayınları, 2018.
3. Gebelikte Kanser Tedavisi. Güneş Tıp Kitabevleri, 2017.

Kaynaklar: 1 · 2 · 3